The James Dyson Foundation has donated £8m to create a technology hub at the heart of Cambridge, providing the University of Cambridge’s brightest engineers with some of the world’s most advanced engineering laboratories.

Some of the UK's most promising entrepreneurs will have access to an innovative new business education programme launched at Imperial today.

Director of UCL Advances and Director of UCL Enterprise Operations, Timothy Barnes, has won the Queen’s Award for Enterprise Promotion.

In the framework of the EU-project Solarjet, scientists demonstrate for the first time the entire production path to liquid hydrocarbon fuels from water, CO2 and solar energy. The key technological component is a solar reactor developed at ETH Zurich.

The structure of sodium channels – which play an essential role in the functioning of heart and nerve cells – are different than previously believed. Researchers hope their discovery will lead to improvements in drugs that act on the sodium channel to treat a range of cardiac and pain conditions.

KTH researchers are helping robots learn to cooperate, a difficult but potentially revolutionary challenge.

A new nano-membrane made out of the “super material” graphene is extremely light and breathable. Not only can this open the door to a new generation of functional waterproof clothing, but also to ultra-rapid filtration. The membrane produced by the researchers at ETH Zurich is as thin as is technologically possible.

Thermal power plants amounts to nearly 70% of all generated electricity worldwide, but also accounts for about one third of the global carbon dioxide emissions. By finding improved high temperature materials, thermal power plants can run more effectively to a lower cost, both economically and environmentally.

Imperial Innovations' portfolio company, Oxford Immunotec Global PLC (NASDAQ: OXFD), has received a Queen’s Award for Enterprise – the UK’s highest accolade in business success.

A team of researchers from five Swedish universities, led by Karolinska Institutet and the Science for Life Laboratory, have identified a new way of treating cancer. The concept is presented in the journal Nature and is based on inhibiting a specific enzyme called MTH1, which cancer cells, unlike normal cells, require for survival. Without this enzyme, oxidized nucleotides are incorporated into DNA, resulting in lethal DNA double-strand breaks in cancer cells.